Medicine
Focalin XR 30 mg extended-release capsule
Focalin XR 30 mg extended-release capsule is a prescription medicine containing Dexmethylphenidate for oral use, marketed by Sandoz, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and…
Key facts
- Active ingredient (INN)
- Dexmethylphenidate
- Brand
- Focalin XR
- Strength
- 30 mg
- Dosage form
- Extended-release capsule
- Route
- Oral
- Packs
- 100 capsules, 30 capsules
- Marketing authorisation holder
- Sandoz
- Manufacturer
- Sandoz2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CII
- ATC code
- N06BA11 Dexmethylphenidate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 May 2005
- Identifiers
- RxCUI 899439, 899441, 899461 +7DailyMed set ID 1a1da905-42a0-4748-9c39-67eca45deccc, 9cf76f62-48aa-4065-94fd-6fc910391ab5NDC 0078-0433, 66758-240Application NDA021802
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 13 November 2001 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Dexmethylphenidate 30 mg extended-release capsule.
Other strengths and forms of Dexmethylphenidate
Clinical summary
Dexmethylphenidate is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is available as extended-release capsules and tablets for oral use. MedsAcross supplies Dexmethylphenidate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DexmethylphenidateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Focalin prescribing information (Sandoz) · U.S. National Library of Medicine, DailyMed
Need Focalin XR 30 mg extended-release capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.